Cantargia

• SEK 59.3m directed share issue via club deal with a selected group of local and international investors, representing a  c. 9% capital increase
• The new shares were issued at SEK 3.55 per new share, corresponding to the volume-weighted average share price on Nasdaq Stockholm on 30 October 2023
• The transaction received strong support from Swedish and international investors including certain existing shareholders, notably the Fourth Swedish National Pension Fund (AP4), the First Swedish National Pension Fund (AP1) and Alecta Tjänstepension
• The company intends to use the issue proceeds to finance (i) preparative work for the phase 2b trial in PDAC for nadunolimab, and (ii) general corporate purposes and the extension of its cash runway into 2025
• The transaction represents Van Lanschot Kempen’s fifth ECM transaction for a Nordic company in 2023, underpinning the ability of Van Lanschot Kempen to support healthcare companies in the region.

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Global Coordinator and Joint Lead Bookrunner in the NOK 505 million Capital Increase by Nykode
• Sole Financial Adviser in the SEK 120 million Structured Equity transaction by SynAct Pharma
• Lead Manager in the USD 1.3 billion Capital Increase by argenx
• Joint Bookrunner in the SEK 500 million Capital Increase by Vicore Pharma
• Financial Adviser to NewAmsterdam Pharma in the USD 182 million secondary sell-down by existing investors 
• Joint Global Coordinator & Joint Bookrunner in the EUR 25 million Capital Increase by Vivoryon Therapeutics
• Joint Global Coordinator & Joint Bookrunner in the EUR 16 million Capital Increase by Sequana Medical
• Lead Manager in the DKK 1.5 billion Capital Increase by Zealand Pharma
• Capital Markets Advisor & Placement Agent in the Merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE
• Lead Manager in the USD 250 million Capital Increase by CureVac
• Sole Financial Adviser to GenSight Biologics in securing a EUR 12 million Credit Facility from Heights Capital Management
• Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
• Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80 million PIPE
• Joint Bookrunner in the SEK 200 million Capital Increase by Vicore Pharma
• Joint Global Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
• Sole Financial Adviser to GenSight Biologics in securing a EUR 35 million Credit Facility from the European Investment Bank
• Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Capital Increase by Xbrane Biopharma
• Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma